Exact Mass: 493.2676
Exact Mass Matches: 493.2676
Found 500 metabolites which its exact mass value is equals to given mass value 493.2676
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Epo A
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent D050258 - Mitosis Modulators > D050256 - Antimitotic Agents > D050257 - Tubulin Modulators D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents Epothilone A is a competitive inhibitor of the binding of [3H] paclitaxel to tubulin polymers, with a Ki of 0.6-1.4 μM.
Imatinib
Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Cytochalasin Npho
Cytochalasin Npho is a mycotoxin from Phomopsis sp Mycotoxin from Phomopsis species
4-[[2-Methyl-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propanoyl]amino]adamantane-1-carboxamide
Epothilone A
Imatinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 2742 INTERNAL_ID 2742; CONFIDENCE standard compound CONFIDENCE standard compound; INTERNAL_ID 8521 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3633
C28H35N3O5_(1R,5R,7S,12R)-12-Hydroxy-4,4,4,4,12,14-hexamethyl-4H,13H-spiro[9,14-diazatetracyclo[5.5.2.0~1,9~.0~3,7~]tetradecane-5,8-[1,4]dioxepino[2,3-g]indole]-9,13(10H)-dione
Ala Glu Phe Lys
Ala Glu Lys Phe
Ala Phe Glu Lys
Ala Phe Lys Glu
Ala Phe Arg Thr
Ala Phe Thr Arg
Ala Ile Gln Tyr
Ala Ile Tyr Gln
Ala Lys Glu Phe
Ala Lys Phe Glu
Ala Leu Gln Tyr
Ala Leu Tyr Gln
Ala Gln Ile Tyr
Ala Gln Leu Tyr
Ala Gln Tyr Ile
Ala Gln Tyr Leu
Ala Arg Phe Thr
Ala Arg Thr Phe
Ala Thr Phe Arg
Ala Thr Arg Phe
Ala Tyr Ile Gln
Ala Tyr Leu Gln
Ala Tyr Gln Ile
Ala Tyr Gln Leu
Glu Ala Phe Lys
Glu Ala Lys Phe
Glu Phe Ala Lys
Glu Phe Lys Ala
Glu Lys Ala Phe
Glu Lys Phe Ala
Phe Ala Glu Lys
Phe Ala Lys Glu
Phe Ala Arg Thr
Phe Ala Thr Arg
Phe Glu Ala Lys
Phe Glu Lys Ala
Phe Ile Asn Thr
Phe Ile Gln Ser
Phe Ile Ser Gln
Phe Ile Thr Asn
Phe Lys Ala Glu
Phe Lys Glu Ala
Phe Lys Leu Ser
Phe Lys Ser Ile
Phe Lys Ser Leu
Phe Lys Thr Val
Phe Lys Val Thr
Phe Leu Lys Ser
Phe Leu Asn Thr
Phe Leu Gln Ser
Phe Leu Ser Lys
Phe Leu Ser Gln
Phe Leu Thr Asn
Phe Asn Ile Thr
Phe Asn Leu Thr
Phe Asn Thr Ile
Phe Asn Thr Leu
Phe Gln Ile Ser
Phe Gln Leu Ser
Phe Gln Ser Ile
Phe Gln Ser Leu
Phe Gln Thr Val
Phe Gln Val Thr
Phe Arg Ala Thr
Phe Arg Thr Ala
Phe Ser Ile Lys
Phe Ser Ile Gln
Phe Ser Lys Ile
Phe Ser Lys Leu
Phe Ser Leu Lys
Phe Ser Leu Gln
Phe Ser Gln Ile
Phe Ser Gln Leu
Phe Thr Ala Arg
Phe Thr Ile Asn
Phe Thr Lys Val
Phe Thr Leu Asn
Phe Thr Asn Ile
Phe Thr Asn Leu
Phe Thr Gln Val
Phe Thr Arg Ala
Phe Thr Val Lys
Phe Thr Val Gln
Phe Val Lys Thr
Phe Val Gln Thr
Phe Val Thr Lys
Phe Val Thr Gln
Gly Arg Val Tyr
Gly Arg Tyr Val
Gly Val Arg Tyr
Gly Val Tyr Arg
Gly Tyr Arg Val
Gly Tyr Val Arg
His Ile Pro Gln
His Ile Gln Pro
His Leu Pro Gln
His Leu Gln Pro
His Pro Ile Gln
His Pro Leu Gln
His Pro Gln Ile
His Pro Gln Leu
His Gln Ile Pro
His Gln Leu Pro
His Gln Pro Ile
His Gln Pro Leu
Ile Ala Lys Tyr
Ile Ala Gln Tyr
Ile Ala Tyr Lys
Ile Ala Tyr Gln
Ile Phe Lys Ser
Ile Phe Asn Thr
Ile Phe Gln Ser
Ile Phe Ser Lys
Ile Phe Ser Gln
Ile Phe Thr Asn
Ile His Pro Gln
Ile His Gln Pro
Ile Lys Ala Tyr
Ile Asn Phe Thr
Ile Asn Thr Phe
Ile Pro His Gln
Ile Pro Gln His
Ile Gln Ala Tyr
Ile Gln Phe Ser
Ile Gln His Pro
Ile Gln Pro His
Ile Gln Ser Phe
Ile Gln Tyr Ala
Ile Ser Phe Gln
Ile Ser Gln Phe
Ile Thr Phe Asn
Ile Thr Asn Phe
Ile Tyr Ala Gln
Ile Tyr Gln Ala
Lys Ala Glu Phe
Lys Ala Phe Glu
Lys Glu Ala Phe
Lys Glu Phe Ala
Lys Phe Ala Glu
Lys Phe Glu Ala
Lys Pro Ser Tyr
Lys Pro Tyr Ser
Lys Ser Pro Tyr
Lys Ser Tyr Pro
Lys Tyr Pro Ser
Lys Tyr Ser Pro
Leu Ala Gln Tyr
Leu Ala Tyr Gln
Leu Phe Asn Thr
Leu Phe Gln Ser
Leu Phe Ser Gln
Leu Phe Thr Asn
Leu His Pro Gln
Leu His Gln Pro
Leu Asn Phe Thr
Leu Asn Thr Phe
Leu Pro His Gln
Leu Pro Gln His
Leu Gln Ala Tyr
Leu Gln Phe Ser
Leu Gln His Pro
Leu Gln Pro His
Leu Gln Ser Phe
Leu Gln Tyr Ala
Leu Ser Phe Gln
Leu Ser Gln Phe
Leu Thr Phe Asn
Leu Thr Asn Phe
Leu Tyr Ala Gln
Leu Tyr Gln Ala
Asn Phe Ile Thr
Asn Phe Leu Thr
Asn Phe Thr Ile
Asn Phe Thr Leu
Asn Ile Phe Thr
Asn Ile Thr Phe
Asn Leu Phe Thr
Asn Leu Thr Phe
Asn Thr Phe Ile
Asn Thr Phe Leu
Asn Thr Ile Phe
Asn Thr Leu Phe
Asn Val Val Tyr
Asn Val Tyr Val
Asn Tyr Val Val
Pro His Ile Gln
Pro His Leu Gln
Pro His Gln Ile
Pro His Gln Leu
Pro Ile His Gln
Pro Ile Gln His
Pro Lys Ser Tyr
Pro Lys Tyr Ser
Pro Leu His Gln
Pro Leu Gln His
Pro Gln His Ile
Pro Gln His Leu
Pro Gln Ile His
Pro Gln Leu His
Pro Ser Lys Tyr
Pro Ser Tyr Lys
Pro Tyr Lys Ser
Pro Tyr Ser Lys
Gln Ala Ile Tyr
Gln Ala Leu Tyr
Gln Ala Tyr Ile
Gln Ala Tyr Leu
Gln Phe Ile Ser
Gln Phe Leu Ser
Gln Phe Ser Ile
Gln Phe Ser Leu
Gln Phe Thr Val
Gln Phe Val Thr
Gln His Ile Pro
Gln His Leu Pro
Gln His Pro Ile
Gln His Pro Leu
Gln Ile Ala Tyr
Gln Ile Phe Ser
Gln Ile His Pro
Gln Ile Pro His
Gln Ile Ser Phe
Gln Ile Tyr Ala
Gln Leu Ala Tyr
Gln Leu Phe Ser
Gln Leu His Pro
Gln Leu Pro His
Gln Leu Ser Phe
Gln Leu Tyr Ala
Gln Pro His Ile
Gln Pro His Leu
Gln Pro Ile His
Gln Pro Leu His
Gln Ser Phe Ile
Gln Ser Phe Leu
Gln Ser Ile Phe
Gln Ser Leu Phe
Gln Thr Phe Val
Gln Thr Val Phe
Gln Val Phe Thr
Gln Val Thr Phe
Gln Tyr Ala Ile
Gln Tyr Ala Leu
Gln Tyr Ile Ala
Gln Tyr Leu Ala
Arg Ala Phe Thr
Arg Ala Thr Phe
Arg Phe Ala Thr
Arg Phe Thr Ala
Arg Gly Val Tyr
Arg Gly Tyr Val
Arg Thr Ala Phe
Arg Thr Phe Ala
Arg Val Gly Tyr
Arg Val Tyr Gly
Arg Tyr Gly Val
Arg Tyr Val Gly
Ser Phe Ile Gln
Ser Phe Leu Gln
Ser Phe Gln Ile
Ser Phe Gln Leu
Ser Ile Phe Gln
Ser Ile Gln Phe
Ser Lys Pro Tyr
Ser Lys Tyr Pro
Ser Leu Phe Gln
Ser Leu Gln Phe
Ser Pro Lys Tyr
Ser Pro Tyr Lys
Ser Gln Phe Ile
Ser Gln Phe Leu
Ser Gln Ile Phe
Ser Gln Leu Phe
Ser Tyr Lys Pro
Ser Tyr Pro Lys
Thr Ala Phe Arg
Thr Ala Arg Phe
Thr Phe Ala Arg
Thr Phe Ile Asn
Thr Phe Leu Asn
Thr Phe Asn Ile
Thr Phe Asn Leu
Thr Phe Gln Val
Thr Phe Arg Ala
Thr Phe Val Gln
Thr Ile Phe Asn
Thr Ile Asn Phe
Thr Leu Phe Asn
Thr Leu Asn Phe
Thr Asn Phe Ile
Thr Asn Phe Leu
Thr Asn Ile Phe
Thr Asn Leu Phe
Thr Gln Phe Val
Thr Gln Val Phe
Thr Arg Ala Phe
Thr Arg Phe Ala
Thr Val Phe Gln
Thr Val Gln Phe
Val Phe Gln Thr
Val Phe Thr Gln
Val Gly Arg Tyr
Val Gly Tyr Arg
Val Asn Val Tyr
Val Asn Tyr Val
Val Gln Phe Thr
Val Gln Thr Phe
Val Arg Gly Tyr
Val Arg Tyr Gly
Val Thr Phe Gln
Val Thr Gln Phe
Val Val Asn Tyr
Val Val Tyr Asn
Val Tyr Gly Arg
Val Tyr Asn Val
Val Tyr Arg Gly
Val Tyr Val Asn
Tyr Ala Ile Gln
Tyr Ala Leu Gln
Tyr Ala Gln Ile
Tyr Ala Gln Leu
Tyr Gly Arg Val
Tyr Gly Val Arg
Tyr Ile Ala Gln
Tyr Ile Gln Ala
Tyr Lys Pro Ser
Tyr Lys Ser Pro
Tyr Leu Ala Gln
Tyr Leu Gln Ala
Tyr Asn Val Val
Tyr Pro Lys Ser
Tyr Pro Ser Lys
Tyr Gln Ala Ile
Tyr Gln Ala Leu
Tyr Gln Ile Ala
Tyr Gln Leu Ala
Tyr Arg Gly Val
Tyr Arg Val Gly
Tyr Ser Lys Pro
Tyr Ser Pro Lys
Tyr Val Gly Arg
Tyr Val Asn Val
Tyr Val Arg Gly
Tyr Val Val Asn
Cytochalasin Npho
7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
[(1S)-2-[(4-chlorophenyl)methyl]-1-(cyclopropylmethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
[(1R)-2-[(4-chlorophenyl)methyl]-1-(cyclopropylmethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3S)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(1R,9S,10S,11S)-12-[2-(dimethylamino)acetyl]-10-(hydroxymethyl)-11-(4-methylpiperazine-1-carbonyl)-5-phenyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(2R,3R)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-8-[2-(3-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
N-[(5R,6R,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5R,6S,9R)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
methyl N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
1-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
methyl N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
(2S,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
1-[[(4R,5R)-8-(1-cyclohexenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
N-[(5R,6R,9R)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5S,6S,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5S,6S,9R)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5S,6R,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
methyl N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
methyl N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
methyl N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
1-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
1-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
1-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
(1S,9R,10R,11R)-12-[2-(dimethylamino)acetyl]-10-(hydroxymethyl)-11-(4-methylpiperazine-1-carbonyl)-5-phenyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
methyl N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
methyl N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
(1S,6R,7R,8R)-6-Hydroxy-4,4,6,10,10,13-hexamethylspiro[10H-[1,4]dioxepino[2,3-g]indole-8,11-3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane]-9,14-dione
[3-acetyloxy-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] (Z)-tetradec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-pentadec-9-enoate
[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-hexadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-tridec-9-enoate
Epothilone A
An epithilone that is epothilone C in which the double bond in the macrocyclic lactone ring has been oxidised to the corresponding epoxide (the 13R,14S diastereoisomer). C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent D050258 - Mitosis Modulators > D050256 - Antimitotic Agents > D050257 - Tubulin Modulators D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents Epothilone A is a competitive inhibitor of the binding of [3H] paclitaxel to tubulin polymers, with a Ki of 0.6-1.4 μM.
phosphatidylethanolamine 18:1 zwitterion
A 1,2-diacyl-sn-glycero-3-phosphoethanolamine zwitterion in which the two acyl groups contain a total of 18 carbons and 1 double bond.
phosphatidylcholine 15:1
A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain a total of 15 carbons and 1 double bond.
(1R,5S,6S,7R,10S,14S,16S)-6,10-dihydroxy-5,7,9,9-tetramethyl-14-[1-(2-methyl-4-thiazolyl)prop-1-en-2-yl]-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione
PC(15:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(4s,7r,8s,9s,13z,15s,16r)-4,8,15-trihydroxy-5,5,7,9-tetramethyl-16-[(1e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione
(1'r,3'r,7's,8r,12'r)-9,12'-dihydroxy-4,4,4',4',12',14'-hexamethyl-9',14'-diazaspiro[[1,4]dioxepino[2,3-g]indole-8,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecan]-13'-one
(4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-16-[(1e)-3-hydroxy-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-5,5,7,9-tetramethyl-1-oxacyclohexadec-13-ene-2,6-dione
14-ethyl-2,6-dihydroxy-4,19-dimethoxy-16-methyl-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosan-21-yl acetate
3-benzyl-1,6,12-trihydroxy-4,10,12-trimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,11h,15h-cycloundeca[d]isoindol-15-yl acetate
(3s,3ar,6s,6ar,10s,12r,15r,15ar)-3-benzyl-1,6,12-trihydroxy-4,5,10,12-tetramethyl-3h,3ah,6h,6ah,9h,10h,11h,15h-cycloundeca[d]isoindol-15-yl acetate
3beta-acetoxynorerythrosuamine
{"Ingredient_id": "HBIN008156","Ingredient_name": "3beta-acetoxynorerythrosuamine","Alias": "3\u03b2-acetoxynorerythrosuamine","Ingredient_formula": "C26H39NO8","Ingredient_Smile": "CC1C2C(CCC1=CC(=O)OCCNC)C3(CCC(C(C3C(=O)C2O)(C)C(=O)OC)OC(=O)C)C","Ingredient_weight": "493.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "25340;265","TCMSP_id": "NA","TCM_ID_id": "8175;24321","PubChem_id": "101606278","DrugBank_id": "NA"}